<DOC>
	<DOCNO>NCT01062763</DOCNO>
	<brief_summary>The purpose study estimate effect spironolactone blood pressure resistant therapy type-2 diabetic .</brief_summary>
	<brief_title>The Effect Spironolactone Blood Pressure Type-2 Diabetics With Resistant Hypertension</brief_title>
	<detailed_description>The primary object study estimate effect addition low dose spironolactone antihypertensive treatment least three antihypertensive drug patient type-2 diabetes blood pressure 130/80 mmHg . Secondary aim estimate many patient blood pressure control addition spironolactone , investigate whether addition spironolactone affect insulin sensitivity urinary protein secretion estimate incidence adverse effect aldosterone antagonist .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Age &lt; 75 year Type2 diabetes Therapy resistant hypertension ( ABPM ) Treatment least 3 antihypertensive HbA1c &gt; 10.0 BP &gt; 180/110 mmHg Secondary hypertension Intolerance spironolactone Permanent treatment nonsteroidal antiinflammatory drug systemic glucocorticoid Total cholesterol 10 mmol/l New York Heart Association class III IV Pregnancy plan pregnancy Psychiatric disease Malignant disease Insufficient adherence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>hypertension</keyword>
	<keyword>spironolactone</keyword>
	<keyword>antihypertensive treatment</keyword>
	<keyword>Type-2 diabetes</keyword>
</DOC>